COMP <GO>
GALT vs RLMD // REVENUE GROWTH (YOY)
Galectin Therapeutics Inc. (NASDAQ) VS. Relmada Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: GALT 2
— RLMD 2
■ METRIC PARITY
LAST: $3.52 (-0.56%) • MKT CAP: $355.8M
revenue-growth
—
LAST: $3.44 (+2.69%) • MKT CAP: $366.9M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GALT VS. RLMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GALT | RLMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.71% | -12.48% | +5.77 | GALT | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | GALT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.7 | 52.9 | -12.24 | RLMD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $355.8M | $366.9M | -$11.2M | RLMD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GALT REV | RLMD REV | GALT GROSS % | RLMD GROSS % | GALT FCF | RLMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$23.9M | -$45.8M |
| FY 2024 | $0 | $0 | — | — | -$41.8M | -$51.8M |
| FY 2023 | $0 | — | — | — | -$33.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GALT // BETA —
RLMD // BETA —